Wednesday, February 19, 2025

Tomocube Aims for KOSDAQ Listing, Pioneers Holotomography for Ethical Drug Testing and Semiconductor Inspection

Tomocube, a trailblazer in the field of holotomography (HT) technology, is gearing up for its KOSDAQ debut with plans to expand its innovative capabilities across industries. At an IPO press conference held at 63 Square in Yeouido, Seoul, on October 23, Tomocube’s CEO Park Yong-geun outlined the company’s strategic goals, emphasizing the critical role HT will play in transforming both the pharmaceutical and semiconductor industries.

With growing global regulatory pressure to reduce animal testing, Tomocube’s HT technology offers a groundbreaking solution. By enabling real-time, high-resolution observation of living organoids without the need for chemical staining, the company is poised to lead a technological revolution that goes far beyond its initial biomedical applications.

Organoids: The Future of Drug Testing?

The pharmaceutical industry is shifting gears. Increasing ethical concerns and tightening regulations around animal testing have pushed major global pharmaceutical companies to invest heavily in alternative methods. One of the most promising advancements? Organoids—3D structures grown from stem cells that closely mimic human organs.

CEO Park explained that all 15 leading pharmaceutical companies worldwide are ramping up their investments in organoid technology. This shift has accelerated since the FDA abolished the mandatory animal testing requirement in the Food, Drug, and Cosmetic Act in 2022.

  • Regulatory pressure in U.S. and Europe has pushed companies toward organoid research.
  • The global organoid market was valued at 1.7 trillion won in 2022.
  • Market growth is expected to average 22.1% annually, reaching 4.5 trillion won by 2027.

Organoids present an ethical and more accurate alternative to animal models in drug development. They offer scientists a new way to test drugs in conditions that closely resemble human biology, something traditional animal testing cannot achieve. As these structures gain prominence, Tomocube’s HT technology is emerging as a key enabler, allowing precise and real-time observation without the need for invasive procedures.

holotomography technology in organoid analysis and semiconductor inspection

Holotomography: A New Era for Biomedical Research

What sets Tomocube apart is its unique holotomography technology. Traditional cell observation methods involve chemical staining, which often introduces toxicity and can lead to cell loss or distortion. HT, however, eliminates this issue, offering a clearer, artifact-free view of living cells.

According to Park, “The technology to observe and analyze organoids, which are human organ analogs, in 3D in real-time without chemical treatment is unique to Tomocube’s holotomography worldwide.” This level of precision has made HT a sought-after tool for pharmaceutical companies as they seek ethical alternatives to animal testing.

Key Advantages of HT Technology Description
Real-time observation Live imaging of cells and organoids without delays or artifacts.
No chemical staining required Eliminates the toxicity risks associated with traditional staining techniques.
High-resolution 3D imaging Provides clear views of internal structures of organoids.

Park envisions a future where HT becomes as integral to biomedical research as computed tomography (CT) is to medical imaging. As the world moves toward more ethical testing methods, HT could become a cornerstone in this transformative era.

Beyond Biomedicine: Holotomography in the Semiconductor Industry

While the focus of Tomocube’s HT technology has been largely on the biomedical field, the company has broader ambitions. Park revealed that the same technology could also be applied to the semiconductor inspection market, a sector where precision and reliability are paramount.

Tomocube’s expansion into semiconductor quality control underscores the versatility of HT. The technology can be used to inspect semiconductor devices, ensuring their reliability and performance, a critical requirement for tech companies.

This diversification adds another dimension to Tomocube’s business model, allowing the company to tap into both the biomedical and semiconductor industries—two of the fastest-growing sectors globally.

IPO and Future Growth: Strategic Use of Funds

As Tomocube prepares for its upcoming KOSDAQ listing, the company is set to use the funds raised from the IPO to expand its operational capacity. This includes scaling its HT technology for broader use, particularly as the demand for organoid testing grows and the semiconductor market continues to thrive.

The company’s commitment to innovation doesn’t stop at HT. Park emphasized that the IPO will enable Tomocube to stay ahead in both the organoid and semiconductor markets by continuously evolving its technology. The funds will be used not only to meet the rising demand but also to invest in future research and development initiatives.

With this move, Tomocube is positioning itself as a leader in both sectors, poised to drive future advancements that could reshape how industries approach testing and quality assurance.

Joshua Garcia
Joshua Garcia
Joshua is a certified personal trainer with a degree in Kinesiology and a fitness blogger with a passion for helping others achieve their health and fitness goals. He also writes about a wide range of topics, including health and wellness, personal development, mindfulness, and sustainable living.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post: